Particulate Matters

Courtesy of Almut MeckeRemoving the positive charge on nanoparticles can improve their chemotherapeutic efficiency, say investigators at the University of Michigan, Ann Arbor. Research presented in March at the annual meeting of the American Physical Society in Montreal showed that without the positive charge, the drug-carrying nanoparticles are less likely to be taken up by normal cells and more likely to be taken up by cancer cells.1 "That way we can direct them to tumor cells and decrease the

Written byHarvey Black
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Courtesy of Almut Mecke

Removing the positive charge on nanoparticles can improve their chemotherapeutic efficiency, say investigators at the University of Michigan, Ann Arbor. Research presented in March at the annual meeting of the American Physical Society in Montreal showed that without the positive charge, the drug-carrying nanoparticles are less likely to be taken up by normal cells and more likely to be taken up by cancer cells.1 "That way we can direct them to tumor cells and decrease the [clinical] side effects," says Almut Mecke, a Michigan doctoral student in biological physics.

Mecke used atomic force microscopy to study charged acrylic acid particles interacting with cell membranes. He found that the positively charged nanoparticles actually damage the membranes of both normal and cancerous cells. But when the researchers replaced positively charged amine groups on the ends of the nanoparticles with neutral acetamide groups, healthy cells were left intact.

The ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies